Treating chronic inflammatory diseases with JAK inhibitors
Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease or ulcerative colitis. Since their approval, the indications for these medical drugs have steadily increased, but recently safety concerns have also been raised. In order to support the safe and efficient use of JAK inhibitors in the treatment of patients, an international panel of experts has published new guidelines.
